| Literature DB >> 34822456 |
Hui Lei1, Xiaoxu Bi2, Xiuping Lin3, Jianglian She3, Xiaowei Luo4, Hong Niu1, Dan Zhang1, Bin Yang3.
Abstract
One strain-many compounds (OSMAC) manipulation of the sponge-derived fungus Pestalotiopsis heterocornis XWS03F09 resulted in the production of new secondary metabolites. The chemical study of the fermentation, cultivated on 3% artificial sea salt in the rice media, led to the isolation of twelve compounds, including eight new polyketide derivatives, heterocornols Q-X (1-8), one new ceramide (9), and three known analogues (10-12). The structures and absolute configurations of the new compounds were elucidated by spectroscopic data and calculated ECD analysis. Heterocornols Q (1) and R (2) are novel 6/5/7/5 tetracyclic polyketide derivatives featuring dihydroisobenzofuran and benzo-fused dioxabicyclo [4.2.1] nonane system, which might be derived from the acetyl-CoA by epoxidation, polyene cyclization, and rearrangement to form the core skeleton. Compound 12 showed moderate or weak antimicrobial activities against with MIC values ranging from 25 to 100 μg/mL. Heterocornols T and X (7 and 8) could inhibit the production of LPS-induced NO significantly, comparable to dexamethasone. Further Western blotting analysis showed 7 and 8 markedly suppressed the iNOS protein expression in LPS-induced RAW 264.7 cells in a dose-dependent manner. The result showed that 7 and 8 might serve as potential leads for development of anti-inflammatory activity.Entities:
Keywords: Pestalotiopsis heterocornis; anti-inflammatory activity; heterocornols; sponge-derived fungus
Mesh:
Substances:
Year: 2021 PMID: 34822456 PMCID: PMC8620458 DOI: 10.3390/md19110585
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–12.
1H NMR (500 MHz) data for 1–4 in CD3OD.
| 1 | 2 | 3 | 4 | |||||
|---|---|---|---|---|---|---|---|---|
| No. | ||||||||
| 1 | 72.4, CH2 | 5.12, dd (12.1, 2.5) | 72.1, CH2 | 5.11, dd (12.0, 2.2) | 31.7, CH2 | 2.81, d (16.4) | 31.7, CH | 2.83, d (8.3) |
| 4.96, dd (12.1, 2.7) | 4.93, dd (12.0, 3.2) | 3.07, dd (16.4, 8.5) | 3.10, dd (16.3, 8.3) | |||||
| 2 | 127.4, C | 127.8, C | 55.6, CH | 2.05, m | 55.5, CH | 2.00, m | ||
| 3 | 153.4, C | 153.5, C | 40.8, CH | 3.75, dd (10.6, 2.3) | 40.9, CH | 3.76, dd (10.6, 2.8) | ||
| 4 | 113.8, CH | 6.58, d (7.9) | 113.7, CH | 6.58, d (7.9) | 147.4, C | 147.2, C | ||
| 5 | 127.1, CH | 7.01, d (7.9) | 126.8, CH | 7.01, d (7.9) | 119.1, C | 119.1, C | ||
| 6 | 129.4, C | 129.2, C | 154.8, C | 154.8, C | 6.63, d (8.0) | |||
| 7 | 143.7, C | 143.7, C | 114.0, CH | 6.63, d (8.1) | 114.0, CH | 6.94, d (8.0) | ||
| 8 | 82.6, CH | 5.50, dd (8.3, 2.5) | 82.5, CH | 5.71, ddt (10.9, 5.6, 2.6) | 124.2, CH | 6.93, d (8.1) | 124.2, CH | 2.79, m |
| 9 | 39.4, CH2 | 2.32, dt (13.5, 4.7) | 35.8, CH2 | 2.32, ddd (14.8, 5.6, 2.5) | 134.0, C | 134.0, C | 2.90, d (2.8) | |
| 1.94, ddd (13.5, 11.3, 2.8) | 1.97, ddd (14.8, 11.2, 4.5) | |||||||
| 10 | 77.3, CH | 4.61, q (6.0) | 77.3, CH | 4.40, q (3.9) | 44.2, CH2 | 2.74, dd (16.2, 10.7) | 43.9, CH2 | 2.79, m |
| 3.01, dd (16.2,2.4) | 2.90, d (2.8) | |||||||
| 11 | 81.4, CH | 4.34, t (2.5) | 78.5, CH | 4.28, dd (6.6, 4.4) | 208.1, C | 208.0, C | ||
| 12 | 74.7, CH | 5.08, q (7.2) | 75.1, CH | 5.06, q (7.1) | ||||
| 13 | 106.4, CH | 5.96, s | 105.3, CH | 5.82, s | 14.8, CH3 | 1.39, d (7.2) | 14.9, CH3 | 1.39, d (7.1) |
| 14 | 21.1, CH3 | 1.30, d (6.2) | 13.0, CH3 | 1.51, d (6.6) | 72.6, C | 72.5, C | ||
| 15 | 25.3, CH3 | 0.91, s | 25.3, CH3 | 0.91, s | ||||
| 16 | 25.7, CH3 | 1.05, s | 25.7, CH3 | 1.05, s | ||||
| 1′ | 64.3, CH2 | 4.48, d (10.6), | 64.3, CH2 | 4.48, d (10.6) | ||||
| 4.60, d (10.6) | 4.60, d (10.6) | |||||||
| 3′ | 65.5, CH2 | 3.57, d (7.0) | 65.4, CH2 | 3.56, dd (7.1, 3.5) | ||||
| 4′ | 14.1, CH3 | 1.20, d (7.0) | 14.1, CH3 | 1.19, d (6.7) | ||||
| AcO | 170.7, C | 170.7, C | ||||||
| 19.1, CH3 | 2.09, s | 19.2, CH3 | 2.10, s | |||||
Figure 2COSY and key HMBC correlations of 1–9.
Figure 3Key NOESY correlations of compounds 1 and 2.
Figure 4Comparison between calculated and experimental ECD spectra of 1–5. (a) for 1 and 2; (b) for 3 and 4; (c) for 5.
1H NMR (500 MHz) data for 5–9.
| 5 a | 6 a | 7 a | 8 a | 9 b | |
|---|---|---|---|---|---|
| No. | |||||
| 1 | 5.06, dd (12.0, 2.7) | 5.04, dd (12.3,2.8) | 5.10, dd (12.0, 3.1) | 5.08, dd (12.1, 2.7) | 4.32, dt (8.1, 4.0) |
| 4.97, d (12.0) | 4.97, dd (12.3) | 4.94, d (12.0) | 4.98, d (12.1) | 4.19, dt (8.1, 3.8) | |
| 2 | 4.21, m | ||||
| 3 | 5.39, d (9.9) | 5.18, dd (10.0, 2.1) | 5.43, brd (9.0) | 5.55, brd (9.0) | 4.20, brs |
| 4 | 5.49, dd (15.4, 6.4) | ||||
| 5 | 6.67, d (7.7) | 6.67, d (7.8) | 5.77, dt (15.4, 6.4) | ||
| 6 | 7.11, t (7.7) | 7.11, t (7.8) | 6.88, d (8.1) | 6.87, d (8.1) | 2.08, m |
| 7 | 6.66, d (7.7) | 6.66, d (7.8) | 6.60, d (8.1) | 6.60, d (8.1) | |
| 8 | 5.08, d (6.4) | ||||
| 10 | 1.84, ddd (14.3, 10.3, 2.3) | 2.08, m | 1.84, dd (6.7, 4.3) | 2.13, m | 1.95, d (7.7) |
| 1.71, ddd (14.3, 10.0, 2.5) | 1.86, dt (4.5, 2.5) | ||||
| 11 | 3.93, ddd (10.3, 4.2, 2.5) | 3.93, ddd (10.2, 4.5, 2.3) | 5.03, ddd (10.0, 4.3, 2.0) | 5.04, ddd (10.0, 4.7, 2.6) | 1.24, m |
| 12 | 4.85, m | 5.05, m | 4.87, dd (6.5, 4.3) | 4.89, dd (6.4, 4.7) | 1.26, m |
| 13 | 1.21, d (6.5) | 1.13, d (6.5) | 1.12, s | 1.23, s | 1.32, m |
| 1 | 3.25, m | 3.36, m | |||
| 2 | 5.54, t (7.0) | 5.45, t (6.5) | 4.11, dt (8.1, 3.8) | ||
| 3 | 1.61, m, 1.81, m | ||||
| 4 | 2.03, s | 2.06, s | 1.42, m | ||
| 5 | 4.48, s | 4.69, s | 1.26, m | ||
| 11-OAc | 2.09, s | 1.61, s | 1.34, m | ||
| 12-OAc | 2.04, s | 1.62, s | |||
| 5-OAc | 2.02, s | 2.04, s | |||
| 1-OAc | 2.06, m | ||||
| 14~17 | 1.24~1.42 | ||||
| 18 | 0.88, t (7.0) | ||||
| 19 | 1.58, brs |
a NMR data for compounds 5–8 in CD3OD, b NMR data for compound 9 in CDCl3 (δ in ppm and J in Hz).
13C NMR (125 MHz) data for 5–9.
| 5 a | 6 a | 7 a | 8 a | 9 b | |
|---|---|---|---|---|---|
| No. | |||||
| 1 | 71.4, CH2 | 71.6, CH2 | 72.8, CH2 | 70.0, CH2 | 62.9, CH2 |
| 2 | 53.0, CH | ||||
| 3 | 82.2, CH | 82.2, CH | 84.1, CH | 83.2, CH | 73.0, CH |
| 4 | 145.4, C | 145.1, C | 142.8, C | 141.8, C | 128.2, CH |
| 5 | 113.0, CH | 113.0, CH | 126.0, C | 126.0, C | 134.4, CH |
| 6 | 130.2, CH | 130.3, CH | 130.7, CH | 130.3, CH | 31.9, CH2 |
| 7 | 114.9, CH | 115.0, CH | 115.6, C | 115.2, CH | 27.5, CH2 |
| 8 | 152.9, C | 153.0, C | 151.3, C | 151.3, C | 123.1, CH |
| 9 | 126.1, C | 126.3, C | 126.1, C | 126.5, C | 136.2, C |
| 10 | 40.4, CH2 | 37.1, CH2 | 38.9, CH2 | 35.0, CH2 | 39.7, CH2 |
| 11 | 71.0, CH | 69.7, CH | 74.7, CH | 72.4, CH | 28.0, CH2 |
| 12 | 75.3, CH | 76.2, CH | 71.5, CH | 74.7, CH | 29.4, CH2 |
| 13 | 15.1, CH3 | 18.4, CH3 | 15.0, CH3 | 15.0, CH3 | 29.4, CH2 |
| 1 | 31.3, CH2 | 31.2, CH2 | 174.6, C | ||
| 2 | 128.7, CH | 129.7, CH | 72.2, CH | ||
| 3 | 132.5, C | 132.4, C | 34.9, CH2 | ||
| 4 | 21.2, CH3 | 21.6, CH3 | 25.0, CH2 | ||
| 5 | 70.9, CH2 | 64.7, CH3 | 28.0, CH2 | ||
| 6~15 | 29.7~31.9 | ||||
| 16 | 14.1, CH3 | ||||
| 11-AcO | 172.4, C | ||||
| 20.8, CH3 | |||||
| 12-AcO | 172.5, C | 172.7, C | 171.4, C | ||
| 21.2, CH3 | 21.1, CH3 | 20.8, CH3 | |||
| 5-AcO | 172.8, C | 172.8, C | |||
| 21.2, CH3 | 20.8, CH3 | ||||
| 1-AcO | 171.3, C | ||||
| 20.9, CH3 | |||||
| 14~17 | 22.7~31.9, CH2 | ||||
| 18 | 14.1, CH3 | ||||
| 19 | 16.0, CH3 |
a NMR data for compounds 5–8 in CD3OD, b NMR data for compound 9 in CDCl3 (δ in ppm and J in Hz).
Figure 5Observed key mass fragments of ceramide 9.
Scheme 1Plausible Biosynthetic Pathway of compounds 1 and 2.
Antibacterial activity of the compounds (MIC, μg/mL).
|
|
|
|
|
|
|---|---|---|---|---|
| 12 | 50 | 25 | 25 | 100 |
| Positive | 0.25 a | 0.13 a | 0.13 a | 1.0 b |
a Ciprofloxacin; b Amphotericin.
Figure 6The anti-inflammatory activity of compounds 7 and 8. Cells were pretreated with both compounds 7 and 8 differently concentrations (0, 3, 11, 33 μM) and DXM (33 μM) for 2 h, then stimulated with or without LPS (1 μg/mL) for 24 h. The culture medium was collected to detect the concentrations of nitrite with Griess agent (A,B). Protein levels of iNOS were evaluated by Western blot (C,D). The data represent the means ± S.E. of three independent experiments. (### p < 0.001 was compared to control. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to LPS group).